Form 10-Q - Quarterly report [Sections 13 or 15(d)]
SEC Accession No. 0001404644-26-000059
Filing Date
2026-08-11
Accepted
2026-08-11 16:57:43
Documents
74
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ngne-20260630.htm   iXBRL 10-Q 1525255
2 EX-10.1 stuartcobbconsultingamendm.htm EX-10.1 17737
3 EX-31.1 ngne-2026formq210xqxex311p.htm EX-31.1 9440
4 EX-31.2 ngne-2026formq210xqxex312p.htm EX-31.2 9556
5 EX-32.1 ngne-2026formq210xqxex321.htm EX-32.1 7122
11 ngne-20260630_g1.jpg GRAPHIC 370698
  Complete submission text file 0001404644-26-000059.txt   8058722

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20260630.xsd EX-101.SCH 49459
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ngne-20260630_cal.xml EX-101.CAL 52443
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ngne-20260630_def.xml EX-101.DEF 233876
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20260630_lab.xml EX-101.LAB 629974
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20260630_pre.xml EX-101.PRE 436543
78 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20260630_htm.xml XML 873137
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36327 | Film No.: 261264192
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)